Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By activating these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, and ultimately